Biodesix INC Form 4 insider transactions

Robin Harper Cowie, CFO, Secretary, and Treasurer of Biodesix Inc., reports the sale of common stock to cover taxes upon the vesting of Restricted Stock Units (RSUs).

Director Charles M. Watts reports the vesting and subsequent disposal of restricted stock units in Biodesix Inc.

Director Charles Watts acquired 46,686 restricted stock units and 37,050 stock options in Biodesix Inc. on May 21, 2024.

Chris Vazquez, Chief Accounting Officer of Biodesix Inc., converted Series A Non-Voting Convertible Preferred Stock into Common Stock on May 23, 2024, following stockholder approval.

Director Matthew Strobeck reports changes in beneficial ownership of Biodesix Inc. stock due to the conversion of Series A Non-Voting Convertible Preferred Stock into common stock, along with the grant of restricted stock units and stock options.

Director Jack Schuler reports the conversion of Series A Non-Voting Convertible Preferred Stock into common stock and the grant of restricted stock units and stock options in Biodesix Inc.

Gary Anthony Pestano, Chief Development Officer of Biodesix Inc., converted Series A Non-Voting Convertible Preferred Stock into Common Stock on May 23, 2024, following stockholder approval.

Kieran O'Kane, Chief Commercial Officer of Biodesix Inc., converted Series A Non-Voting Convertible Preferred Stock into 13,080 shares of Common Stock on May 23, 2024, following stockholder approval.

Director Hany Massarany reports the acquisition of restricted stock units and stock options in Biodesix Inc. on May 21, 2024.

Lawrence Kennedy Jr., a director and 10% owner of Biodesix Inc., reports changes in beneficial ownership due to the conversion of Series A Non-Voting Convertible Preferred Stock into common stock and the grant of restricted stock units and stock options.

Director Jon Faiz Kayyem reports acquisition of restricted stock units and stock options in Bio-Rad Laboratories.

Biodesix CEO Scott Hutton converted Series A Non-Voting Convertible Preferred Stock into common stock following stockholder approval at the company's annual meeting.

Director Jean M. Franchi reports the acquisition of restricted stock units and stock options in Biodesix Inc. on May 21, 2024.

Robin Harper Cowie, CFO, Secretary, and Treasurer of Biodesix Inc., reports transactions involving common stock and derivative securities.

John Patience, Chairman of Bio-Rad Laboratories, reports acquisition of common stock and stock options following the conversion of Series A Non-Voting Convertible Preferred Stock.

Chris Vazquez, Chief Accounting Officer of Biodesix Inc., reports the acquisition and disposal of common stock and restricted stock units.

Gary Anthony Pestano, Chief Development Officer of Biodesix Inc., sold shares of common stock to cover taxes upon the vesting of restricted stock units (RSUs).

Chief Commercial Officer Kieran O'Kane reports acquisition and disposal of Biodesix Inc. stock, including shares sold to cover taxes upon RSU vesting.

Biodesix CEO Scott Hutton reports acquisition and disposal of company stock, including shares sold to cover taxes upon RSU vesting.

Robin Harper Cowie, CFO, Secretary, and Treasurer of Biodesix Inc., reports the acquisition and disposal of common stock and restricted stock units.

Chris Vazquez, Chief Accounting Officer of Biodesix Inc., acquired 22 shares of Series A Non-Voting Convertible Preferred Stock on April 5, 2024, pending stockholder approval for conversion into common stock.

Matthew Strobeck, a director of Biodesix Inc., acquired Series A Non-Voting Convertible Preferred Stock that can be converted into common stock pending stockholder approval.

Director Jack Schuler acquired Series A Non-Voting Convertible Preferred Stock in Bio-Rad Laboratories, pending stockholder approval for conversion into common stock.

Gary Anthony Pestano, Chief Development Officer of Biodesix Inc., acquired Series A Non-Voting Convertible Preferred Stock on April 5, 2024, which may convert into common stock pending stockholder approval.

John Patience, Chairman at Biodesix Inc, reports acquisition of Series A Non-Voting Convertible Preferred Stock, pending stockholder approval for conversion into common stock.

Kieran O'Kane, Chief Commercial Officer of Biodesix, acquired Series A Non-Voting Convertible Preferred Stock on April 5, 2024, pending stockholder approval for conversion into common stock.

Lawrence T. Kennedy Jr., a director and 10% owner of Biodesix Inc., acquired Series A Non-Voting Convertible Preferred Stock, which is contingent on stockholder approval for conversion into common stock.

Scott Hutton, President & CEO of Biodesix Inc., acquired Series A Non-Voting Convertible Preferred Stock on April 5, 2024, which is subject to stockholder approval for conversion into common stock.

Robin Harper Cowie, CFO, Secretary, and Treasurer of Biodesix Inc., acquired 327 shares of Series A Non-Voting Convertible Preferred Stock on April 5, 2024.

Director Charles M. Watts reported a transaction involving Biodesix Inc. common stock and restricted stock units on April 1, 2024.